$SGMOQ

SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.03 Bankruptcy or Receivership. The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Compan

SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2

Sangamo Therapeutics (SGMOQ) sold its Fabry disease gene therapy program to PTC Therapeutics for $111M upfront, with up to $100M in milestones. The deal is part of Sangamo's Chapter 11 restructuring, with a bankruptcy court hearing scheduled for September 10, 2026. The transaction is subject to court approval and regulatory milestones.

SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. As previously announc